Vision 2030, regulatory support and rising disease burdens are driving CAR-T, CRISPR and R&D, creating opportunities in localized, commercial-scale manufacturing.

Dublin, Sept. 16, 2026 (GLOBE NEWSWIRE) -- "Saudi Arabia Cell and Gene Therapy Manufacturing Market: Industry Trends and Future Forecast, Till 2035 - Distribution by Type of Therapy, Type of Scale, Type of Mode, Type of Workflow, Type of Process, Type of Technology, End User and Leading Players" has been added to ResearchAndMarkets.com's offering.

Saudi Arabia Cell and Gene Therapy Manufacturing Market Projected to Reach USD 722 Million by 2035

The Saudi Arabia cell and gene therapy market is estimated at USD 133 million in the current year and is projected to reach USD 722 million by 2035. The market is expected to expand at a compound annual growth rate of 21% during the forecast period, supported by healthcare investment, regulatory progress, research and development initiatives, and growing demand for advanced treatments targeting cancer, genetic disorders, rare diseases, and chronic conditions.

Saudi Arabia Cell and Gene Therapy Manufacturing Market Growth and Trends

Cell and gene therapy manufacturing is emerging as an important component of Saudi Arabia's Vision 2030 healthcare transformation. National initiatives focused on biotechnology, precision medicine, localized production, and advanced clinical research are creating opportunities for therapy developers, pharmaceutical companies, biotechnology businesses, contract manufacturing organizations, and technology providers.

Saudi Arabia is increasing its focus on personalized treatments, including CAR-T cell therapies and CRISPR-based gene-editing programs. Regulatory developments led by the Saudi Food and Drug Authority, together with research conducted by organizations such as King Faisal Specialist Hospital and Research Centre, are helping strengthen the country's clinical and manufacturing capabilities. These developments are expected to support sustained market expansion through 2035.

Strategic Drivers Supporting Market Expansion

The rising prevalence of cancer, inherited disorders, and other chronic diseases is increasing demand for targeted therapeutic approaches. Government funding for research and development, healthcare infrastructure, clinical programs, and domestic biomanufacturing is also contributing to market growth. Localization initiatives may improve treatment availability, strengthen supply-chain resilience, and reduce dependence on imported products and manufacturing services.

Regulatory progress is another important growth factor. Dedicated requirements for advanced therapy clinical trials and closer alignment with international standards can streamline development pathways while strengthening quality, safety, and compliance. Continued collaboration among hospitals, research institutions, regulators, therapy developers, and manufacturing partners will be critical to market development.

Manufacturing Challenges and Market Opportunities

Despite a growing clinical pipeline, cell and gene therapy manufacturing remains technically and operationally complex. Key challenges include targeted delivery, process scale-up, cell harvesting, product stability, raw material consistency, quality testing, cold-chain management, and regulatory compliance. Limited specialized talent and the capital-intensive nature of advanced manufacturing infrastructure may also affect commercialization timelines.

These challenges are encouraging stakeholders to invest in process development, automation, analytical technologies, quality systems, and scalable production platforms. Companies capable of supporting integrated development and manufacturing workflows are expected to benefit as more therapies progress from research programs into clinical and commercial production.

Cell Therapies Hold the Largest Market Share

Cell therapy manufacturing is projected to account for approximately 60% of the Saudi Arabia cell and gene therapy market. This position is supported by increasing interest in stem cell therapies, non-stem cell therapies, and CAR-T cell treatments, particularly for oncology applications. Gene therapies are anticipated to record strong growth during the forecast period as research into genetic mutations expands and additional programs advance toward clinical evaluation and commercialization.

Research and Development Leads by Manufacturing Scale

Precommercial and research-scale manufacturing currently represents nearly 70% of the market. The segment benefits from an expanding therapy pipeline and rising investment in early-stage development, clinical research, process optimization, and production capacity. Commercial-scale manufacturing is expected to grow more rapidly as global regulatory approvals increase and demand rises for viral vectors, plasmid DNA, engineered cells, and associated testing services.

Key Market Segments

Therapy type: Cell therapies, including stem cell and non-stem cell therapies, and gene therapies
Manufacturing scale: Precommercial and R&D-scale manufacturing, and commercial-scale manufacturing
Workflow: Cell processing, cell banking, process development, fill-and-finish operations, analytical and quality testing, raw material testing, vector production, and other workflows
Process: Upstream processes and downstream processes
Technology: Fluorescence-activated cell sorting, enzyme-linked immunosorbent assay, chromatography, next-generation sequencing, polymerase chain reaction, and other technologies
End user: Pharmaceutical companies, biopharmaceutical and biotechnology companies, and contract manufacturing organizations

Companies Included in the Market Landscape

Organizations evaluated within the competitive and service-provider landscape include CMED, ICON, Labcorp, Linical, Lonza, Medpace, Novartis, Novotech, PharmaLex, PPD, Precision for Medicine, QPS, Roche, Syneos Health, Thermo Fisher Scientific, and WuXi AppTec.

Key Questions Addressed by the Report

What are the current and projected values of the Saudi Arabia cell and gene therapy market?
Which companies and organizations are active in the market?
What trends are influencing cell and gene therapy manufacturing in Saudi Arabia?
Which growth drivers, barriers, and opportunities are expected to shape the market through 2035?
What manufacturing and regulatory challenges affect industry participants?
How will market opportunities be distributed across therapy types, manufacturing scales, workflows, processes, technologies, and end users?
Which segments are expected to record the highest growth during the forecast period?

Reasons to Purchase the Report

Access detailed revenue forecasts for the overall Saudi Arabia cell and gene therapy manufacturing market and its principal subsegments.
Evaluate market drivers, restraints, emerging opportunities, competitive developments, and operational challenges.
Identify potential investment, partnership, research, localization, and manufacturing opportunities.
Assess customer requirements and changing demand across pharmaceutical, biotechnology, and contract manufacturing organizations.
Support market-entry planning, competitive positioning, and evidence-based business strategy development.
Improve stakeholder engagement using structured market intelligence and segment-level analysis.

Complementary Benefits

Excel data packs covering all analytical modules
Up to 15% content customization
Detailed report walkthrough with the research team
Complimentary report update when the purchased report is more than six months old

Key Attributes:

Report Attribute	Details
No. of Pages	100
Forecast Period	2026 - 2035
Estimated Market Value (USD) in 2026	$133 Million
Forecasted Market Value (USD) by 2035	$722 Million
Compound Annual Growth Rate	21.0%
Regions Covered	Saudi Arabia

Key Topics Covered:

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Value and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross-Border Dynamics
4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of Cell and Gene Therapies
6.3. Classification of Cell and Gene Therapies
6.4. Therapeutic Areas Targeted by Cell and Gene Therapies
6.5. Challenges in the Cell and Gene Therapy Domain
6.6. Recent Developments in the Cell and Gene Therapy Domain

7. MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Saudi Arabia Cell and Gene Therapy Market: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Location of Manufacturing Facility
7.2.5. Analysis by Source of Cells
7.2.6. Analysis by Scale of Operation
7.2.6.1. Analysis by Type of Additional Service Offered

8. COMPANY PROFILES: SAUDI ARABIA CELL AND GENE THERAPY MARKET
8.1. Chapter Overview
8.2. CMED
8.2.1. Company Overview
8.2.2. Product Portfolio
8.2.3. Financial Information
8.2.4. Recent Developments and Future Outlook
8.3. ICON
8.4. Labcorp
8.5. Linical
8.6. Lonza
8.7. Medpace
9.8. Novartis
8.9. Novotech
8.10. Pharmalex
8.11. PPD
8.12. Precision for Medicine
8.13. QPS
8.14. Roche
8.15. Syneos Health
8.16. Thermo Fisher Scientific
8.17. Wuxi AppTec

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Saudi Arabia Cell and Gene Therapy Manufacturers: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Most Active Players: Analysis by Number of Partnerships
9.3.4. Analysis by Geography
9.3.4.1. Intercontinental and Intracontinental Agreements
9.3.4.2. Local and International Agreements

10. MARKET IMPACT ANALYSIS
10.1. Chapter Overview
10.2. Market Drivers
10.3. Market Restraints
10.4. Market Opportunities
10.5. Market Challenges
10.6. Conclusion

11. SAUDI ARABIA CELL AND GENE THERAPY MANUFACTURING MARKET
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Saudi Arabia Cell and Gene Therapy Market: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
11.4. Analyst's Perspective on Market Growth
11.5 Scenario Analysis
11.5.1. Conservative Scenario
11.5.2. Optimistic Scenario
11.6. Key Market Segmentations

12. SAUDI ARABIA CELL AND GENE THERAPY MARKET, BY TYPE OF THERAPY
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Saudi Arabia Cell and Gene Therapy: Distribution by Type of Therapy
12.3.1. Cell Therapies, Historical Trends (Since 2022) and Forecasted (Till 2035)
12.3.2. Gene Therapies, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
12.4. Data Triangulation and Validation

13. SAUDI ARABIA CELL AND GENE THERAPY MARKET, BY TYPE OF SCALE
13.1. Chapter Overview
13.2. Assumptions and Methodology
13.3. Saudi Arabia Cell and Gene Therapy Market: Distribution by Type of Scale
13.3.1. Precommercial / R&D Scale Manufacturing: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
13.3.2. Commercial Scale Manufacturing: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
13.4. Data Triangulation and Validation

14. SAUDI ARABIA CELL AND GENE THERAPY MARKET, BY TYPE OF WORKFLOW
14.1. Chapter Overview
14.2. Assumptions and Methodology
14.3. Saudi Arabia Cell and Gene Therapy Market: Distribution by Type of Offering
14.3.1. C Cell Processing: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
14.3.2. Cell Banking: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
14.3.3. Process Development: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
14.3.4. Fill & Finish Operations: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
14.3.5. Analytical & Quality Testing: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
14.3.6. Raw Material Testing: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
14.3.7. Vector Production: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
14.3.8. Other Workflow: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
14.4. Data Triangulation and Validation

15. SAUDI ARABIA CELL AND GENE THERAPY MARKET, BY TYPE OF PROCESS
15.1. Chapter Overview
15.2. Assumptions and Methodology
15.3. Saudi Arabia Cell and Gene Therapy Market: Distribution by Type of Process
15.3.1. Upstream Process: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
15.3.2. Downstream Process: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
15.4. Data Triangulation and Validation

16. SAUDI ARABIA CELL AND GENE THERAPY MARKET, BY TYPE OF TECHNOLOGY
16.1. Chapter Overview
16.2. Assumptions and Methodology
16.3. Saudi Arabia Cell and Gene Therapy Market: Distribution by Type of Technology
16.3.1. Fluorescence-Activated Cell Sorting (FACS): Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
16.3.2. Enzyme-Linked Immunosorbent Assay (ELISA): Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
16.3.3. Chromatography: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
16.3.4. Next-Generation Sequencing (NGS): Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
16.3.5. Polymerase Chain Reaction (PCR): Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
16.3.6. Other Technologies: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
16.4. Data Triangulation and Validation

17. SAUDI ARABIA CELL AND GENE THERAPY MARKET, BY END USER
17.1. Chapter Overview
17.2. Assumptions and Methodology
17.3. Saudi Arabia Cell and Gene Therapy Market: Distribution by End User
17.3.1. Pharmaceutical Companies: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.3.2. Biopharmaceutical / Biotechnological Companies: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.3.3. Contract Manufacturing Organizations: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
17.4. Data Triangulation and Validation

18. CONCLUDING REMARKS

19. APPENDIX I: TABULATED DATA

20. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

A selection of companies mentioned in this report includes, but is not limited to:

CMED
ICON
Labcorp
Linical
Lonza
Medpace
Novartis
Novotech
Pharmalex
PPD
Precision for Medicine
QPS
Roche
Syneos Health
Thermo Fisher Scientific
Wuxi AppTec

For more information about this report visit https://www.researchandmarkets.com/r/jav5fw

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900

Saudi Arabia Cell and Gene Therapy Manufacturing Market Poised for Growth Through 2035, Fueled by Advanced Technologies, Scalable Production and Rising End-User Demand